Why research peptides come with no dose or mixing instructions

No FDA-reviewed human dose exists for unapproved research peptides, so this page explains why, what FDA says can go wrong, and where to get legitimate care instead.

Basics7 min read

Key takeaway

A dose is a finding, not a guess. For an approved medicine, it comes from clinical trials that FDA reviews, and it is written into the drug's label. BPC-157, MOTS-c, TB-500, CJC-1295 and ipamorelin have no FDA approval, so no label and no reviewed dose exist. FDA says it lacks the information to know whether several of them would cause harm in people. Research-grade peptides are for laboratory research only, not for human or veterinary use.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited1
Related productsResearch peptide catalog

Many people who search peptide dosage want to know how much BPC-157, MOTS-c, TB-500, CJC-1295 or ipamorelin to use. The honest answer is that no one can tell you, because no FDA-reviewed human dose exists for any of them. This page explains why, what FDA says about these compounds, what can go wrong, and where to get real medical care. Sources were checked on November 17, 2026.

Quick answer: There is no approved or established human dose for BPC-157, MOTS-c, TB-500, CJC-1295, ipamorelin or other unapproved research peptides. FDA has not reviewed them for safety or effectiveness in people. For approved peptide medicines, the dose comes from the FDA label and a licensed prescriber. Research-grade peptides are laboratory reagents, and we do not give dosing, mixing or reconstitution instructions for any of them.

Why is there no dose for research peptides?

A safe dose has to be found by testing in people, under medical supervision, and then checked by a regulator. For approved drugs, FDA rules say the label's dosage section "must state the recommended dose" for the product. Where appropriate, it must also give an upper limit beyond which safety and effectiveness are unproven (21 CFR 201.57, 2026).

None of that exists for an unapproved research peptide. A Drugs@FDA search on November 17, 2026 found no approved application for BPC-157, MOTS-c, thymosin beta-4 fragments, CJC-1295 or ipamorelin (Drugs@FDA, 2026). A number on a forum, a chart or a calculator is not a reviewed dose. No regulator has checked it for safety in people.

What has FDA said about BPC-157, MOTS-c, TB-500, CJC-1295 and ipamorelin?

FDA reviewed these peptides when they were nominated for use in pharmacy compounding. Its findings sit on a page listing bulk substances that may present significant safety risks (FDA, 2026). Table 1 quotes FDA's own words. The 2026 sport status comes from the World Anti-Doping Agency (WADA, 2026).

Table 1

What FDA has said about five popular research peptides (checked November 17, 2026)

Peptide FDA-approved drug? What FDA wrote WADA 2026 list
BPC-157 No "No, or only limited, safety-related information"; FDA "lacks sufficient information to know whether the drug would cause harm when administered to humans" Named under S0, prohibited at all times
MOTS-c No FDA "has not identified any human exposure data" and notes possible significant immunogenicity risk Not named; check with your anti-doping body
TB-500 (thymosin beta-4 fragment) No FDA "has not identified any human exposure data" and "lacks important information regarding any safety issues" Named under S2, prohibited at all times
CJC-1295 No "Serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction"; clinical data "are limited" Named under S2, prohibited at all times
Ipamorelin acetate No A published study reported "serious adverse events including death" with one form of administration; still in FDA's 503B category 2 Named under S2, prohibited at all times

FDA also lists immunogenicity and peptide-related impurities as concerns for most of these compounds. Immunogenicity means the body's immune system may react to the peptide or its impurities. BPC-157, MOTS-c, TB-500 and CJC-1295 are now listed as "previously in category 2" because their nominators withdrew them. Withdrawn is not approved. Our pages on peptides and the FDA in 2026 and whether BPC-157 is legal explain what that change did and did not do.

Where does the dose come from for approved peptide medicines?

Some peptides are real, FDA-approved medicines. Semaglutide, tirzepatide, tesamorelin (EGRIFTA WR), bremelanotide (Vyleesi) and setmelanotide (Imcivree) all have FDA labels on DailyMed (DailyMed, 2026). For these, a licensed prescriber sets the dose from the label, after looking at your health and your other medicines. We link the labels instead of quoting doses:

What can go wrong when people dose research peptides themselves?

FDA and others have documented several ways things go wrong when unapproved peptide products end up in people.

  • Unknown contents. FDA says illegally marketed drugs sold online could contain "the wrong ingredients or harmful ingredients" or "too little, too much or no active ingredient at all." It calls research-labeled GLP-1 products sold for human use "of unknown quality" (FDA, 2026).
  • Contamination. A 2024 study bought semaglutide vials from illegal online sellers. Every sample contained endotoxin, a bacterial toxin, and purity was far below the label's claim (Ashraf et al., 2024).
  • Infection. CDC warns that unsafe injections "can spread diseases like hepatitis C, hepatitis B, bacterial and fungal diseases" (CDC, 2024).
  • Dosing errors. Even with prescribed compounded semaglutide, FDA received reports of adverse events, some requiring hospitalization, after people measured the wrong amount (FDA, 2024).

Our page on the risks of using research peptides on yourself covers each of these in more detail, with no instructions of any kind.

Why won't Vitrapep explain reconstitution or dosing?

We supply laboratory reagents. We do not give dosing, mixing, reconstitution or administration information for any compound, for three reasons.

  • There is no safe number to give. No reviewed human dose exists, so any figure we printed would be a guess dressed up as fact.
  • The products are not medicines. Research-grade peptides are sold for laboratory research use only, not for human or veterinary use. They are not made or tested as medicines for people.
  • Instructions change what a product is. FDA judges a product's intended use from labeling, advertising and the circumstances of sale (21 CFR 201.128). It has warned sellers whose research-labeled products were "sold directly to consumers for human use with dosing instructions."

A "research use only" label does not, by itself, make it legal to sell or use a product for people. Our guide to FDA warning letters to peptide sellers shows how FDA has applied that rule.

Where can you get legitimate care?

  • A licensed clinician. A doctor, nurse practitioner or physician assistant can tell you whether an approved medicine fits your goal, and at what dose.
  • A clinical trial. Registered trials are the lawful way to receive an investigational drug. Search ClinicalTrials.gov, and see how to find a peptide clinical trial.
  • A licensed pharmacy. If you buy medicine online, FDA's BeSafeRx program explains how to check a pharmacy.
  • If something goes wrong. Call 911 in an emergency. Poison Help at 1-800-222-1222 is free, confidential and open 24 hours a day (MedlinePlus, 2025).
  • Report it. Tell FDA through MedWatch, online or at 1-888-INFO-FDA (1-888-463-6332), option 2 (FDA, 2025).

Frequently asked questions about research peptide dosage

What is the right peptide dosage?

For unapproved research peptides, there is no right dosage, because no FDA-reviewed human dose exists. For approved peptide medicines, a licensed prescriber sets the dose from the FDA label.

Is there an approved dose of BPC-157?

No. BPC-157 is not an approved drug, and FDA says it lacks sufficient information to know whether it would cause harm in humans.

Is there an approved dose of MOTS-c?

No. MOTS-c is not an approved drug, and FDA says it has not identified any human exposure data on products containing it.

What is the TB-500 dose?

There is none. TB-500 is not an approved drug, FDA has not identified any human exposure data, and WADA prohibits it at all times.

What is the CJC-1295 and ipamorelin dose?

Neither has an approved or established human dose. FDA has cited serious adverse events with both, and WADA prohibits both at all times.

Is there a peptide dosing chart I can trust?

Not for unapproved peptides. Charts and calculators online are not reviewed by FDA, and they assume a vial holds exactly what its label says.

Why won't Vitrapep explain peptide reconstitution or dosing?

Our products are laboratory reagents, not for human or veterinary use, and no reviewed human dose exists to share. Giving instructions would also present research material as something to use in people.

What to know now

  • No dose: unapproved research peptides have no FDA-reviewed human dose.
  • FDA's view: for BPC-157, MOTS-c and TB-500, FDA says it lacks the safety information to know whether they would cause harm.
  • Approved medicines: the label and a licensed prescriber set the dose.
  • Risks: unknown contents, contamination, infection and dosing errors are all documented.
  • Help: 911 in an emergency, Poison Help at 1-800-222-1222, and FDA MedWatch.
  • Research grade: laboratory reagents, not for human or veterinary use.

What we're watching

Any FDA decision on adding peptides to the 503A bulks list, the final version of HHS's October 2026 draft peptide compounding policy, and new FDA warning letters to sellers of research-labeled peptides.

Also in the library

Sources: U.S. Food and Drug Administration 2026; Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57; Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses" . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128, 21 CFR 201.128: Meaning of "intended uses"; U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (searched November 17, Drugs@FDA: FDA-approved drugs; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; National Library of Medicine. DailyMed: EGRIFTA WR (tesamorelin), DailyMed: EGRIFTA WR (tesamorelin), Theratechnologies; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; Ashraf 2024, Journal of Medical Internet Research; Centers for Disease Control and Prevention 2024, About injection safety; U.S. Food and Drug Administration 2024; U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information . https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information, BeSafeRx: Your source for online pharmacy information; National Library of Medicine 2025, MedlinePlus: Poison control center, emergency number; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA; U.S. National Library of Medicine. ClinicalTrials.gov . https://clinicaltrials.gov/, ClinicalTrials.gov. All 14 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57
  3. Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses". https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128
  4. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (searched November 17, 2026). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  5. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  6. National Library of Medicine. DailyMed: EGRIFTA WR (tesamorelin), Theratechnologies. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  7. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  8. Ashraf, A. R., Mackey, T. K., Vida, R. G., et al. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. Journal of Medical Internet Research, 26, e65440. https://pubmed.ncbi.nlm.nih.gov/39509151/
  9. Centers for Disease Control and Prevention. (2024). About injection safety. https://www.cdc.gov/injection-safety/about/index.html
  10. U.S. Food and Drug Administration. (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  11. U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
  12. National Library of Medicine. (2025). MedlinePlus: Poison control center, emergency number (reviewed January 8, 2025). https://medlineplus.gov/ency/article/002724.htm
  13. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (content current as of September 26, 2025). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
  14. U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/